Alternatively,it could serve as a competitive probe in high-throughput screens forsmall molecules that disrupt the PALB2–BRCA2 interface, pavingthe way toward novel treatments tailored to exploit synthetic lethalvulnerabilities across diverse cancer genotypes. The gene discussed is PALB2; the disease is cancer.